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Abstract
Background: We evaluated the utility of L-3,4-dihydroxy-6-[
18F]fluoro-phenylalanine ([
18F]FDOPA) positron emission
tomography (PET) as a method for assessing the severity of dopaminergic dysfunction in unilaterally 6-
hydroxydopamine (6-OHDA)-lesioned rats by comparing it with quantitative biochemical, immunohistochemical,
and behavioral measurements.
Methods: Different doses of 6-OHDA (0, 7, 14, and 28 μg) were unilaterally injected into the right striatum of male
Sprague-Dawley rats. Dopaminergic functional activity in the striatum was assessed by [
18F]FDOPA-PET,
measurement of striatal dopamine (DA) and DA metabolite levels, tyrosine hydroxylase (TH) immunostaining, and
methamphetamine-induced rotational testing.
Results: Accumulation of [
18F]FDOPA in the bilateral striatum was observed in rats pretreated with both aromatic
L-amino acid decarboxylase and catechol-O-methyltransferase (COMT) inhibitors. Unilateral intrastriatal injection of
6-OHDA produced a significant site-specific reduction in [
18F]FDOPA accumulation. The topological distribution
pattern of [
18F]FDOPA accumulation in the ipsilateral striatum agreed well with the pattern in TH-stained
corresponding sections. A significant positive relationship was found between Patlak plot Ki values and striatal
levels of DA and its metabolites (r = 0.958). A significant negative correlation was found between both Ki values (r
= -0.639) and levels of DA and its metabolites (r = -0.719) and the number of methamphetamine-induced
rotations.
Conclusions: Ki values determined using [
18F]FDOPA-PET correlated significantly with the severity of dopaminergic
dysfunction. [
18F]FDOPA-PET makes it possible to perform longitudinal evaluation of dopaminergic function in 6-
OHDA-lesioned rats, which is useful in the development of new drugs and therapies for Parkinson’s disease (PD).
Keywords: Parkinson’s disease, positron emission tomography, [
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Background
Parkinson’s disease is a progressive, chronic neurode-
generative disorder with movement dysfunction that pri-
marily affects the elderly [1]. The four main symptoms
of Parkinson’s disease (PD; tremor, rigidity, bradykinesia,
and postural instability) grow worse over time with a
severe decrease in striatal dopamine (DA) content
resulting from neuron loss in the substantia nigra pars
compacta (SNc) projecting into the striatum (caudate
and putamen).
Treatment of PD is primarily based on DA replacement
using the dopamine pro-drug, levodopa (L-DOPA).
Although L-DOPA remains the most effective therapy,
chronic treatment causes adverse effects, such as
wearing-off phenomenon and dyskinesia [2]. Gene and
stem cell therapies have attracted attention as L-DOPA
alternatives. Recent studies involving rodent and
nonhuman primate models of PD suggested that trans-
plantation of dopamine neurons derived from mouse,
monkey, or human embryonic stem cells and delivery of
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provided the original work is properly cited.dopamine-synthesizing enzymes or glial cell line-derived
neurotrophic factor genes using recombinant adeno-
associated viral vector into the nigral DA neurons and/or
the striatal cells can provide motor benefits[3-9].
Rats unilaterally lesioned with 6-hydroxydopamine
(6-OHDA) are a useful hemi-Parkinson model for study-
ing DA-related functions. This model also aids new drug
and novel therapy research because motor deficits (e.g.,
drug-induced rotation) can be quantified [10]. Different
PD models can be developed by varying the site of
6-OHDA injection between the medial forebrain bundle
(MFB), SNc, or caudate-putamen complex (CPu). The
MFB and SNc lesion models, and partial DA depletion
in the CPu model, mimic advanced and global PD
stages, respectively [11].
Positron emission tomography (PET) can detect
impairment of dopaminergic function in living brain.
The fluorinated positron-emitting analog of L-DOPA,
L-3,4-dihydroxy-6-[
18F]fluoro-phenylalanine ([
18F]
FDOPA), is one of the most widely used PET tracers for
studying the brain dopaminergic system. Accumulation
of [
18F]FDOPA in the brain reflects its transport, decar-
boxylation, and vesicular uptake in the nigrostriatal pre-
synaptic nerve terminals. In PD patients, [
18F]FDOPA
uptake in the striatum is reduced [12-14], and there is a
negative correlation between the degree of motor deficit
and [
18F]FDOPA uptake, especially in the putamen
[15-19]. Other analogs used include (+)-[
11C]dihydrote-
trabenazine ([
11C]DTBZ), which binds specifically to
vesicular monoamine transporter 2 (VMAT2) in dopa-
minergic synaptic vesicles, and [
18F]b-CFT (2-b-carbo-
methoxy-3b-(4-fluorophenyl)tropane or WIN-35,428), a
dopamine transporter (DAT)-selective radioligand. A
significant correlation between [
11C]DTBZ-binding and
clinical motor asymmetry and a clear association of the
severity of rigidity and hypokinesia with reduced [
18F]b-
CFT uptake in the putamen have been reported [20],
underscoring the usefulness of PET for PD diagnosis
and assessment of lesion severity.
Recent developments in small animal PET imaging
instrumentation have enabled noninvasive, quantitative,
and repetitive visualization of biological functions in liv-
ing animals. From a translational research perspective,
in vivo molecular imaging with small animal disease
models bridges the gap between laboratory research and
human clinical studies. Many PET studies of presynaptic
dopaminergic function in 6-OHDA-lesioned rats have
been reported [21-32]. Inaji et al. [28] reported a signifi-
cant negative hyperbolic correlation between the num-
ber of methamphetamine-induced rotations and the
binding activity of [
11C]PE2I, a selective DAT radioli-
gand. Though DAT ligands are reportedly superior for
detecting decreases in DA neurons [33-35], [
18F]FDOPA
enables examination of dopaminergic neuron functions
including transport, decarboxylation, and vesicular
uptake, which is useful for assessing the neuroprotective
e f f e c t so ft h e r a p e u t i ca g e n t s ,a sw e l la se v a l u a t i n gt h e
differentiation of grafted cells in living brains. Especially,
in the cell transplantation experiments into the striatum
or gene therapy experiments, it is considered that eva-
luation of overall dopaminergic neuron functions using
[
18F]FDOPA-PET is useful for interpreting these thera-
peutic effects on differentiation or enhancement of
dopaminergic neurons, whereas the accumulation of
DAT ligands in the striatum means the expression of
functional DAT protein, which is nothing more than a
proof of the function of DA reuptake.
The severity of lesions induced by 6-OHDA injection
is generally evaluated by biodistribution analysis, ex vivo
autoradiography, or assessment of rotational behavior
[33,36]. A few rodent PD model studies using [
18F]
FDOPA-PET which present no images of the specific
uptake of [
18F]FDOPA were reported to date [23,27].
Therefore, quantitative assessment of lesion severity
using [
18F]FDOPA-PET has also not been reported. In
this study, we quantitatively analyzed [
18F]FDOPA-PET
in unilaterally 6-OHDA-lesioned rats, and report the
first accurate evaluation of the severity of dopaminergic
dysfunction using [
18F]FDOPA-PET.
Methods
Chemicals
6-OHDA (Sigma Chemical Co., St. Louis, MO, USA)
was dissolved in saline (Otsuka Pharmaceutical Co.,
Ltd., Tokyo, Japan) containing 0.2% (w/v)L - a s c o r b i c
acid (Wako Pure Chemical Industries, Ltd., Osaka,
Japan). Methamphetamine sulfate (Dainippon Sumitomo
Pharma Co. Ltd., Osaka, Japan) was dissolved in saline.
Entacapone (Novartis Pharma, Tokyo, Japan), a periph-
eral catechol-O-methyltransferase (COMT) inhibitor,
and carbidopa (Sigma), a peripheral aromatic L-amino
acid decarboxylase (AADC) inhibitor, were suspended in
0.25% sodiumcarboxymethylcellulose. All solutions and
suspensions were prepared fresh.
Labeling synthesis
[
18F]FDOPA was synthesized according to a slightly
modified previously reported method [37]. Briefly, 4-O-
pivaloyl-L-dopa (PharmaSynth As, Tartu, Estonia) was
dissolved in acetic acid and acetyl [
18F]hypofluorite was
bubbled through the solution at 130°C for 10 min. The
reaction mixture was then hydrolyzed in 6 M HCl at
room temperature for 3 min. The product was purified
using high-performance liquid chromatography (HPLC)
on a COSMOSIL 5C18-MS-II column (20 mm (i.d.) ×
250 mm, 5-μm, Nacalai Tesque, Kyoto, Japan) using
0.1% acetic acid as the mobile phase. The purified frac-
tion was mixed with 25% ascorbic acid (Ascorbic Acid
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Japan) and sterilized by filtration before administration.
Each solution was prepared on the day of the experi-
ment. The pH of the final solution for animal use was
around 6.0. Specific radioactivity at the time of injection
ranged from 11 to 70 MBq/μmol. The radiochemical
purity was over 99.5%.
Animals
Thirty-five 6-OHDA unilaterally lesioned male Sprague-
Dawley rats were purchased from Japan SLC, Inc. (Shi-
zuoka, Japan). The animals were maintained in a tem-
perature- and light-controlled environment with
standard food and tap water provided ad libitum.A l l
experimental protocols were approved by the Ethics
Committee on Animal Care and Use of the Center for
Molecular Imaging Science in RIKEN, and were per-
formed in accordance with the Principles of Laboratory
Animal Care (NIH publication no. 85-23, revised 1985).
Unilateral 6-OHDA lesioning
Stereotaxic surgery was performed at Japan SLC as fol-
lows. Eight-week-old animals were anesthetized with
pentobarbital sodium (50 mg/kg, i.p.) and placed in the
stereotaxic head holder so that the difference in the DV
value between bregma and lambda was ≤ 0.1 mm. Two
microlitres of 6-OHDA solution were injected into each
of four sites in the right striatum (site 1: AP +1.3, ML
-2.6, DV -5.0 mm; site 2: AP +0.4, ML -3.0, DV -5.0
mm; site 3: AP -0.4, ML -4.2, DV -5.0 mm; site 4: AP
-1.3, ML -4.5, DV -5.0 mm relative to bregma and ven-
tral from the dura) at a rate of 1 μl/min using a 10-μl
Hamilton microsyringe. After injection, the needle was
left in place for 1 min before being slowly withdrawn.
The total doses of 6-OHDA (free base) were 7 μg( n =
10), 14 μg( n = 10), and 28 μg( n = 11). Sham-treated
control animals (n = 4) were injected with saline instead
of 6-OHDA but otherwise treated identically.
PET scans
A microPET Focus220 scanner (Siemens, Knoxville, TN,
USA) with a 1.4-mm spatial resolution (FWHM) at the
center of a view with 220 mm diameter and an axial
extent of 78 mm was used for all PET scans. Rats were
selected randomly and placed into groups of six animals.
The sham-operated control group was composed of
three animals. At 6 to 12 weeks after 6-OHDA lesion-
ing, rats weighing 397 to 489 g were anesthetized and
maintained with a mixture of 1.5% isoflurane and
nitrous oxide:oxygen (7:3). Body temperature was moni-
tored during anesthesia and maintained at 37°C. At the
start of the emission scan, a single bolus of [
18F]FDOPA
was administered via the tail vein at a dose of 108 to
151 MBq/kg, representing a calculated chemical amount
of [
18F]FDOPA of 0.74 to 5.57 μmol/animal. Thirty min-
utes before tracer administration, rats were premedi-
cated with carbidopa (10 mg/kg, i.p.) or both carbidopa
(10 mg/kg, i.p.) and entacapone (10 mg/kg, i.p.) [33]. A
minimum 1-week washout separated PET scans in the
same rat.
A 3D list-mode emission scan was performed for 90
min and sorted into 41 frame-dynamic sinograms as fol-
l o w s :6×1 0s ,6×3 0s ,1 1×6 0s ,1 5×1 8 0s ,3×6 0 0
s. PET images were reconstructed using microPET man-
ager 2.4.1.1 (Siemens, Knoxville, TN, USA) by Fourier
Rebinning and standard 2D filtered back projection
(FBP) using a ramp filter with a cutoff at the Nyquist
frequency.
Image analysis
Images were analyzed using PMOD software (version
3.15; PMOD Technologies Ltd., Zurich, Switzerland).
MRI images were collected 7 weeks after rats were 6-
OHDA unilaterally lesioned and were manually aligned
in space using a rat brain atlas [38]. MRI images of con-
trol rats of the same age were coregistered with those of
lesioned rats. Using the rat brain atlas for guidance,
regions of interest (ROI) were placed on each striatum
and the cerebellum on the aligned MRI template. Each
region was primarily drawn on coronal slices and then
confirmed on sagittal and horizontal slices. PET images
of lesioned and control rats were manually coregistered
to the corresponding MRI templates. All related ROIs
were stacked into the volume of interest (VOI), and the
mean value in each VOI was used to generate regional
time-activity curves (TACs). TACs for each tissue were
constructed by normalizing decay-corrected time-radio-
activity measurements to the standardized uptake value
(SUV) of [
18F]FDOPA.
Kinetic analysis
Uptake of [
18F]FDOPA in normal or lesioned striatum
tissues was calculated by Patlak plots [39] using PMOD
software. The activity of a reference TAC devoid of
tracer trapping replaced the blood activity. The radioac-
tivity profile from 10 to 60 min after [
18F]FDOPA
administration was used. The [
18F]FDOPA influx con-
stant was determined using the following equation:
CTissue(t)
CReference(t)
= Ki
t 
0
CReference(u)du
CReference(t)
+ V,
where CTissue(t) represents the tissue radioactivity
concentration at time t as determined by PET image
analysis. CReference(t) represents the reference tissue
(cerebellum) radioactivity concentration at time t as
determined by PET image analysis. Ki represents the
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18F]FDOPA influx constant calculated from the regres-
sion slope. V represents the initial distribution volume
in the tissue of interest at time 0, calculated from the
Patlak plot y-intercept.
HPLC analysis of radio-metabolites in plasma
Plasma radio-metabolites were analyzed to confirm the
effect of pretreatment with carbidopa and entacapone
on the metabolism of [
18F]FDOPA by peripheral
COMT and DDC. Venous blood was collected from
the tail vein after the emission scan and centrifuged at
12 000 rpm for 2 min at 4°C. A fivefold volume of
cold 0.2 M perchloric acid containing 100 μM
Na2EDTA was then added and the resulting suspen-
sion was centrifuged at 15,000 rpm for 15 min at 4°C,
filtered through a 0.45 μm PTFE filter (Millipore, Bill-
erica, MA, USA), and an aliquot was injected onto a
HPLC system (Shimadzu Corporation, Kyoto, Japan)
with a UG-SCA30 NaI(TI) positron detector (Universal
Giken, Kanagawa, Japan). Radio-metabolites were sepa-
rated on an EICOMPAK SC-5ODS column (3.0 mm (i.
d.) × 150 mm; Eicom Corporation, Kyoto, Japan) using
0.1 M sodium citrate-acetate buffer (pH 3.5) contain-
ing 17% methanol, 0.88 mM sodiumoctanesulfonic
acid, and 0.013 mM Na2EDTA as the mobile phase.
The analysis was carried out at a column temperature
o f2 5 ° Ca n daf l o wr a t eo f0 . 5m l / m i n .M a j o r
18F peaks
were identified by comparing retention times with
those of authentic metabolite standards. The individual
peak areas of the radiometric chromatograms were
corrected for radioactive decay to the retention time of
the radio-metabolite for each sample and expressed as
fractions of total radioactivity.
Monoamine quantitation
At least 6 days separated PET scanning and sacrificing
for the determination of monoamine level in the stria-
tum, in the meantime we performed the post-scan pro-
cesses including reconstruction, image analysis, kinetic
analysis, and metabolite analysis to confirm the suc-
cesses of PET scanning. In addition, behavioral
abnormality and level of tyrosine hydroxylase (TH)
immunohistochemistry were stable from 6 to 18 weeks
after the unilaterally 6-OHDA-lesioned rats (our perso-
nal data), indicating that a period between PET scan-
ning and sacrificing, within 6 days, may not be
critically influenced on the results using the animals
within 18 weeks after the lesion. At 10 to 16 weeks
after lesioning, animals (control group: n =4 ;7μg
group: n =9 ;1 4μgg r o u p :n =9 ;2 8μgg r o u p :n =7 )
were anesthetized with 1.5% isoflurane and decapi-
tated. Each brain was rapidly removed, rinsed in
chilled saline, and dissected from the lesioned and
unlesioned striata over ice. Striatal tissues were
transferred into pre-weighed plastic tubes and stored
at -80°C until use.
To measure the levels of monoamines and the meta-
bolites DA, 3,4-dihydroxyphenylacetic acid (DOPAC),
homovanilic acid (HVA), serotonin (5-HT), and 5-
hydroxyindoleacetic acid, striatal tissue was homoge-
nized for 30 s in 0.2 M perchloric acid containing 100
μMN a 2EDTA, kept on ice for at least 30 min, then cen-
trifuged at 20,000 × g at 4°C for 15 min. The superna-
tant was diluted twofold in 0.2 M perchloric acid
containing 100 μMN a 2E D T A ,3 0n go fi s o p r o t e r e n o l
internal standard was added, and the pH was adjusted
to approximately 3.0 with 1 M sodium acetate. The
resulting solution was filtered (0.45 μmP T F Ef i l t e r ,
Millipore) and 10 μl was analyzed by HPLC. DA, 5-HT,
and their metabolites were electrochemically detected
using an amperometric detector (ECD-700S; Eicom Cor-
poration, Japan) by oxidation on a graphite electrode at
0.75 V relative to the Ag-AgCl reference electrode. The
amount of monoamines (expressed as nanomoles per
gram tissue) was determined by comparing the ratio of
the monoamine peak area to that of the internal stan-
dard applied to calibration curves.
Tyrosine hydroxylase immunohistochemistry
One representative rat from each 6-OHDA-lesioned
g r o u pe x c e p tt h ec o n t r o lw a su s e df o rT Hi m m u n o h i s -
tochemistry at 12 to 13 weeks after lesioning. Rats were
deeply anesthetized with pentobarbital and perfused
transcardially with saline containing heparin (10 units/
ml) followed by 4% paraformaldehyde in 0.1 M phos-
phate buffer (pH 7.4). Brains were removed and fixed in
the same fixative at 4°C for 2 days. Tissues were cryo-
protected in 15% to 30% sucrose solution and frozen on
dry-ice. Sections of 40 μm were cut using a sliding
microtome (Retoratome REM-700, Yamato Kohki Indus-
trial Co., Ltd., Saitama, Japan) with a refrigeration unit
(Electro Freeze MC-802A, Yamato Kohki Industrial Co.,
Ltd.). Sections were heated in antigen retrieval solution
(0.01 M citrate buffer, pH 6.0) at 90°C for 15 min,
chilled in water, then immersed for 5 min in PBS con-
taining 0.3% Triton X-100 (TPBS). Endogenous peroxi-
dase activity was quenched for 30 min in PBS
containing 0.3% H2O2. After three 5-min washes in
TPBS, sections were preincubated with blocking solution
(Block Ace™; DS Pharma Biomedical Co., Ltd., Osaka,
Japan) at room temperature for 60 min and incubated
overnight at 4°C with a 1:30,000 dilution of mouse anti-
TH monoclonal antibody (ImmunoStar, Inc., Hudson,
WI, USA) in blocking solution. Sections were washed
with TPBS for 5-min three times and incubated with
peroxidase-labeled anti-mouse IgG-specific secondary
antibody (Nichirei Histofine
® Simple Stain Rat MAX
PO (M), Nichirei Biosciences Inc., Tokyo, Japan) at
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washes with TPBS, the reaction was visualized using
3,3-diaminobenzidine as a chromogen. Dehydrated sec-
tions were mounted on glasss l i d e sa n dc o v e r e dw i t h
coverslips.
Rotational behavior
All rats were tested for rotational behavior induced by
methamphetamine (2.5 mg/kg, i.p.) at 8 to 9 weeks after
lesioning. Rotational behaviors were recorded for 90
min with a video camera. Full 360° turns in the direc-
tion ipsilateral to the lesion (clockwise) were counted. A
minimum 4-day washout period separated PET scanning
and behavioral testing.
Statistical analysis
All results were expressed as the mean ± S.D. Conven-
tional statistical analyses were carried out using Graph-
Pad Prism (version 5.02, GraphPad Software, Inc., San
Diego, CA, USA). The paired Student’s t test was used
to compare Ki values and the levels of tissue DA and its
metabolites in the lesioned and contralateral sides
within the same dose groups. Inter-group comparisons
involved one-factor analysis of variance (ANOVA) fol-
l o w e db yp o s th o cD u n n e t t ’s testing. Statistical signifi-
cance was set at P < 0.05. Correlation between
measurements was analyzed by linear regression using
data from rats in which values for all three measures
were available.
Results
Effect of carbidopa and entacapone on striatal
accumulation of [
18F]FDOPA
[
18F]FDOPA-PET studies using sham-operated,
unlesioned control rats pretreated with carbidopa and
entacapone indicated that [
18F]FDOPA accumulates
highly in the bilateral striatum rather than other regions,
including the cerebellum. In rats unilaterally lesioned
with 28 μg of 6-OHDA, [
18F]FDOPA uptake in the stria-
tum was significantly lower in the ipsilateral (right) side
compared to the contralateral (left) side of the injection
(Figure 1b, “C+E ”). The difference was larger in rats
pretreated with carbidopa and entacapone than in rats
pretreated with carbidopa only (Figure 1b, “C”). Figure
1c shows the radiochromatograms of [
18F]FDOPA in the
plasma of the rat shown in Figure 1b collected after PET
scanning. One major peak with a retention time identi-
cal to that of authentic [
18F]FDOPA (3.8 min) was
detected in the plasma from the rat pretreated with car-
bidopa and entacapone. This peak was small in the
plasma from the rat pretreated with carbidopa only, and
there was a later peak with a retention time identical to
that of authentic 3-O-methyl-FDOPA (OMFD) (6.0
min) (data not shown).
Correlation between PET measurements of [
18F]FDOPA
uptake and TH immunohistochemistry
Figure 2 shows coronal PET images and corresponding
photomicrographs of TH-immunostained sections from
6-OHDA-injected rats. Uptake of [
18F]FDOPA in the
contralateral (left) striatum was high and similar in all
rats, while uptake was low in the ipsilateral (right) stria-
tum and along the 6-OHDA injection site, especially in
the dorsal part of the striatum, which was consistent
with immunostaining results.
PET assessment of 6-OHDA-induced dopaminergic
denervation
Time-activity curves indicated decreased accumulation
in the ipsilateral (right) striatum compared to the con-
tralateral (left) striatum, suggesting that 6-OHDA
administration induced degeneration of the dopaminer-
gic synaptic terminals (Figure 3a). Values of Ki,t h e[
18F]
FDOPA influx constant, were significantly lower for the
ipsilateral striatum compared to the contralateral side.
One-way ANOVA revealed that 6-OHDA treatment sig-
nificantly reduced the Ki values for the ipsilateral stria-
tum (F = 14.27, P < 0.0001), but not for the
contralateral striatum (Figure 3b). The individual Ki
right/left ratios (Ki R/L) were plotted against the 6-
OHDA dose (Figure 3c). The mean Ki R/L of the 6-
OHDA groups were lower than the control group, but
in the 7- and 14-μg-dose groups, individual values were
scattered, indicating that the degree of denervation var-
ied among these rats.
Biochemical assessment of 6-OHDA-induced
dopaminergic denervation
The DA content in the ipsilateral striatum was signifi-
cantly lower than in the contralateral striatum in the 6-
OHDA-injected groups (Figure 4a). Inter-group compar-
ison by ANOVA revealed that DA levels on the ipsilat-
eral side were significantly reduced by 6-OHDA
treatment. Dunentt’s posthoc comparisons indicated a
significant decrease in DA levels in the 7- and 28-μg
groups compared to the control group, but no difference
in the contralateral striatum. As shown in Figure 4b, a
similar tendency was observed when the levels of DA
and DA metabolites were summed, indicating that DA
was the major catecholamine component of the stria-
tum. Three kinds of DA-metabolites (DOPAC, HVA,
and 3-O-methyltyramine (3-MT)) were detected in the
striatum. DOPAC (10% to 24% of catecholamine com-
ponent) was more abundant than HVA and 3-MT in
the striatum (3.6% to 6.4% and 2.7% to 4.0%, respec-
tively). The percentage ratio of the level of DA and DA-
metabolites in the right and left striatum (DA-metabo-
lites R/L) plotted against the 6-OHDA dose was lower
in the 6-OHDA groups compared to the control group
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dual differences were large (Figure 3c), indicating a
highly variable degree of striatal dopaminergic denerva-
tion in these animals.
Correlation between PET, biochemical, and behavioral
measurements
Figure 5a illustrates the significant correlation between
the Ki R/L and the DA-metabolites R/L. The Ki R/L nega-
tively correlated with the common logarithm of the num-
ber of methamphetamine-induced rotations (Figure 5b),
and the DA-metabolites R/L negatively correlated with
the behavioral measurements (Figure 5c).
Discussion
Ours is the first report of the use of [
18F]FDOPA-PET
imaging in a rat PD model to discriminate the striatum
from other cerebral structures. Although [
18F]FDOPA is
widely used in primate PET studies, there are few
reports of its use in rodents and there are no specific
PET images of [
18F]FDOPA accumulation in the stria-
tum in these reports [23,27].
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Figure 1 [
18F]FDOPA-PET images of rats and radiochromatograms of rat plasma samples after the administration of [
18F]FDOPA. (a)
Representative [
18F]FDOPA-PET image of a sham-operated control rat coregistered with MRI template at 7 weeks after sham operation. PET
image was reconstructed using FBP and summated from 11 to 90 min after the tracer injection. Blue broken lines in both panels and red lines
in right panel indicate ROIs (striatum and cerebellum, respectively). L = left striatum; R = right striatum. (b) Effect of carbidopa (C) and
entacapone (E) on striatal accumulation of [
18F]FDOPA in 6-OHDA-lesioned rats. PET images were summated from 11 to 90 min after tracer
injection. One rat from the 6-OHDA 28 μg group was scanned in the presence of both inhibitors (left panel, “C+E ”), and after 2 weeks the
same rat was scanned in the presence of carbidopa (right panel, “C”). L = left striatum; R = right striatum. (c) Radiochromatograms of authentic
[
18F]FDOPA and plasma obtained from each rat in (b) after PET scan completion. [
18F]FDOPA (peak at 3.8 min) was detected in the plasma from
the rat pretreated with carbidopa and entacapone (C + E), whereas it was low and the other metabolite, may be 3-O-methyl-FDOPA, existed
mainly (peak at 6.0 min) in the plasma from the rat pretreated with carbidopa only (C).
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18F]FDOPA is primarily metabolized to [
18F]fluoro-
dopamine ([
18F]FDA) by AADC in the peripheral tis-
sues and to [
18F]OMFD by COMT [40]. Therefore, in
order to ameliorate the accumulation of radiotracer in
the striatum, co-administration of the AADC inhibitor
carbidopa and peripheral COMT inhibitor entacapone
was necessary prior to [
18F]FDOPA-PET (Figure 1)
[33]. In addition, the high spatial resolution of micro
PET and superior image reconstruction process we
used enabled successful PET imaging with [
18F]FDOPA
in rodents [41].
Radio-metabolite analysis of plasma sampled after the
emission scan (90 min) revealed that [
18F]FDOPA was
almost intact in rats pretreated with carbidopa and enta-
capone, but was metabolized to [
18F]OMFD in rats trea-
ted only with carbidopa (Figure 1). Pauwels et al. [42]
showed that [
18F]FDA (the major metabolite), [
18F]
FDOPA, [
18F]OMFD, and [
18F]FDOPAC are present in
the striatum of rats pretreated with both carbidopa and
entacapone, while [
18F]OMFD is the major striatum
metabolite in rats pretreated only with carbidopa 30
min after [
18F]FDOPA injection. Therefore, the same
components of
18F-radioactivity might have contributed
to the striatum radioactivity we observed.
The topological distribution of [
18F]FDOPA accumula-
tion we observed in both the dorsal and ventral striatum
(nucleus accumbens) agreed well with TH immunostain-
ing of the corresponding sections, indicating that small
animal PET imaging can provide detailed information
regarding tracer location in the brain. This is particu-
larly useful for evaluating the dopaminergic function of
grafted cells because the accumulation of [
18F]FDOPA
at graft sites would suggest the existence of TH-positive
neurons that have differentiated from grafted cells.
Values of the [
18F]FDOPA influx rate constant Ki for
the left striatum of all groups and the right striatum of
t h ec o n t r o lg r o u pr a n g e df r o m1 5 . 7t o1 6 . 7×1 0
-3 min
-
1. Using a noninvasive approach to determine Ki,T a k i -
kawa et al. reported a mean Ki
OCC value of 6.6 ± 1.8 ×
10
-3 min
-1 in healthy volunteers pretreated with carbi-
dopa [19]. In baboons without pretreatment, the mean
Ki values for the caudate and putamen of control ani-
mals were 6.9 ± 1.2 and 7.7 ± 1.8 × 10
-3 min
-1 [35]. The
Ki value also reflects the blood-brain barrier (BBB)
influx rate and the transport function of system L,
which is composed of the L-type amino acid transporter
1 (LAT1) and 4F2hc [43]. System L transports large
neutral amino acids including leucine, tryptophan, tyro-
sine, phenylalanine, and amino acid related drugs such
as L-DOPA, alpha-methyldopa, melphalan, and gabapen-
tin [44]. Our results suggest that L-DOPA transport
across the rat BBB is greater than transport across the
human BBB, which is consistent with a previous study
showing that the mean rate of phenylalanine uptake and
levels of LAT1 and 4F2hc in isolated brain microvessels
are lower in humans than in rodents [45].
It is noteworthy that there was a significant positive
correlation between the Ki R/L and the striatal DA-
metabolites R/L, although with both of these parameters
there was no clear dose-dependency in the 7- and 14-μg
6-OHDA groups. Postmortem measurements revealed
that the levels of DA and its metabolites in the striatal
1
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V
 
6-OHDA: 7 g 14  g 28  g 
Figure 2 Comparison between [
18F]FDOPA-PET images and TH immunostaining. Upper panels show summated coronal PET images (from
11 to 90 min) of representative rats injected with 7 μg (left), 14 μg (middle), and 28 μg (right) of 6-OHDA. Lower panels show
photomicrographs of TH-immunostained sections corresponding to PET images from the same rats. Scale bar = 100 μm.
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Page 7 of 12lesions varied between the 7- and 14-μgg r o u p s .O u r
data thus suggest that [
18F]FDOPA-PET is also useful
for screening striatal lesions (e.g., prior to cell transplan-
tation experiments).
Although the right/left ratio of Ki values correlated
well with striatal levels of DA and its metabolites, the
linear regression curve did not pass through the origin.
Even in the 28 μg group, which showed the most severe
lesions, the right/left ratio of Ki values ranged from
25.0% to 39.5%, whereas the striatal DA-metabolites R/L
ranged from 4.9% to 29.8%. Similarly, Ito et al. [34]
reported that the regression intercept in plots of the
remaining percentage of DA neurons in SNc versus per-
cent of striatal [
14C]L-DOPA-specific uptake did not
intersect with the origin. One possible explanation for
this result is that the [
18F]FDOPA-PET Ki value reflects
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Figure 3 Effect of 6-OHDA on time profiles of the tissue radioactivity in brain and Ki values.A f t e rt h ea d m i n i s t r a t i o no f[
18F]FDOPA in
rats. (a) Time-activity curves for the radioactivity in the contralateral striatum, ipsilateral striatum, and cerebellum. (b) Ki values in the bilateral
striata of the different dosage groups (0 μg, n = 3; 7, 14, and 28 μg, n = 6). Asterisk (*): significant difference vs. the contralateral side; paired
Student’s t test; number sign (#): significant difference vs. the 0 μg group, one-way ANOVA followed by Dunnett’s multiple comparison test. (c)
Ki values expressed as the percentage ratio of the ipsilateral (right) to the contralateral (left) side for each 6-OHDA dose group.
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minergic neurons, but also by serotonergic terminals,
capillary endothelium, pericytes, and different types of
non-monoaminergic neurons in the striatum, since
these have been reported to show DDC activity and to
be sites of L-DOPA conversion to DA after dopaminer-
gic denervation [46-56].
As shown Figure 5b, the Ki R/L values correlated line-
arly with the common logarithm of the number of rota-
tions induced by methamphetamine. A similar
correlation between percent of striatal [
14C] L-DOPA-
specific uptake and the number of methamphetamine-
induced rotations was reported by Ito and colleagues
[34]. We also showed that the striatal DA-metabolites
R/L values correlated with the behavioral measurements,
which is consistent with previous reports [57,58]. These
results indicate that [
18F]FDOPA-PET is ideal for nonin-
vasive, accurate quantitative evaluation of dopaminergic
function. It might be quite valuable to measure the
recovery of dopaminergic function in cell transplanta-
tion experiments using 6-OHDA-lesioned rats, since dis-
crepancies between recovery of motor deficit and the
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Figure 4 Dose profiles of 6-OHDA on the striatal DA and its metabolite contents. The influence of 6-OHDA on the striatal level of (a) DA,
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Page 9 of 12number of TH
+ cells counted in postmortem analysis
have been reported [59,60]. Considering such animal-to-
animal variation, longitudinal in vivo PET imaging in
individual grafted rats would be quite informative.
Conclusions
This is the first report demonstrating the utility of [
18F]
FDOPA-PET for imaging dopaminergic function in uni-
laterally 6-OHDA-lesioned rats. The severity of the
dopaminergic denervation determined by [
18F]FDOPA-
P E Tc o r r e l a t e dw e l lw i t ht h a td e t e r m i n e db yw i d e l y
used biochemical, immunohistological, and behavioral
assays. [
18F]FDOPA-PET enables noninvasive, quantita-
tive evaluation of dopaminergic function in 6-OHDA-
lesioned rats and will be a useful tool in the develop-
ment of new therapies for PD.
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